NL8200732A - Nieuwe 5-aminomethyl oxazolidineverbindingen, werkwijze ter bereiding daarvan en hun therapeutische toepassing. - Google Patents
Nieuwe 5-aminomethyl oxazolidineverbindingen, werkwijze ter bereiding daarvan en hun therapeutische toepassing. Download PDFInfo
- Publication number
- NL8200732A NL8200732A NL8200732A NL8200732A NL8200732A NL 8200732 A NL8200732 A NL 8200732A NL 8200732 A NL8200732 A NL 8200732A NL 8200732 A NL8200732 A NL 8200732A NL 8200732 A NL8200732 A NL 8200732A
- Authority
- NL
- Netherlands
- Prior art keywords
- formula
- compounds
- group
- chg
- chain
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000001225 therapeutic effect Effects 0.000 title description 3
- JHIJSCYWNFGQHR-UHFFFAOYSA-N 1,3-oxazolidin-5-ylmethanamine Chemical class NCC1CNCO1 JHIJSCYWNFGQHR-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 64
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- -1 (3-chloro-4-fluoro) phenyl group Chemical group 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000000543 intermediate Substances 0.000 claims description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 5
- 108010062431 Monoamine oxidase Proteins 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RYVBINGWVJJDPU-UHFFFAOYSA-M tributyl(hexadecyl)phosphanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[P+](CCCC)(CCCC)CCCC RYVBINGWVJJDPU-UHFFFAOYSA-M 0.000 description 2
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- WLMRGCLTPBIEPE-UHFFFAOYSA-N 4-(4-ethoxy-3-fluorophenyl)aniline Chemical compound C1=C(F)C(OCC)=CC=C1C1=CC=C(N)C=C1 WLMRGCLTPBIEPE-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 241000928106 Alain Species 0.000 description 1
- LZLNXNWSOPBHRN-UHFFFAOYSA-N C1=CC(OCC)(Cl)CC=C1C1=CC=C(N)C=C1 Chemical compound C1=CC(OCC)(Cl)CC=C1C1=CC=C(N)C=C1 LZLNXNWSOPBHRN-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MOMWFXLCFJOAFX-UHFFFAOYSA-N OOOOOOOO Chemical compound OOOOOOOO MOMWFXLCFJOAFX-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
- C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8103797A FR2500450A1 (fr) | 1981-02-25 | 1981-02-25 | Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique |
| FR8103797 | 1981-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8200732A true NL8200732A (nl) | 1982-09-16 |
Family
ID=9255633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8200732A NL8200732A (nl) | 1981-02-25 | 1982-02-24 | Nieuwe 5-aminomethyl oxazolidineverbindingen, werkwijze ter bereiding daarvan en hun therapeutische toepassing. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4476136A (cs) |
| JP (1) | JPS5838273A (cs) |
| AU (1) | AU553462B2 (cs) |
| BE (1) | BE892270A (cs) |
| CA (1) | CA1178594A (cs) |
| CH (1) | CH653999A5 (cs) |
| DE (1) | DE3206770A1 (cs) |
| ES (2) | ES509848A0 (cs) |
| FR (1) | FR2500450A1 (cs) |
| GB (2) | GB2094299B (cs) |
| IT (1) | IT1153437B (cs) |
| LU (1) | LU83963A1 (cs) |
| NL (1) | NL8200732A (cs) |
| SE (1) | SE457258B (cs) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8506659A1 (es) * | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
| US4705799A (en) * | 1983-06-07 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents |
| CA1260948A (en) * | 1984-12-05 | 1989-09-26 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents |
| DE3779525T2 (de) * | 1986-09-03 | 1993-02-11 | Delalande Sa | 5-aminomethyl-2-oxazolidinon-derivate, ihre herstellung und ihre anwendung in der heilkunde. |
| FR2609029B1 (fr) * | 1986-12-30 | 1989-12-08 | Delalande Sa | Derives 5-aminoethyles de l'oxazolidinone-2, leur procede de preparation et leur application en therapeutique |
| FR2603279B1 (fr) * | 1986-09-03 | 1988-12-16 | Rech Ind | Benzyloxy-phenyl-oxazolidinones, procede de preparation et utilisation en therapeutique |
| DE3723797A1 (de) * | 1987-07-18 | 1989-01-26 | Merck Patent Gmbh | Oxazolidinone |
| US5036093A (en) * | 1987-10-09 | 1991-07-30 | Du Pont Merck Pharmaceutical | Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents |
| US5032605A (en) * | 1987-10-09 | 1991-07-16 | Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents |
| US5036092A (en) * | 1987-10-09 | 1991-07-30 | Du Pont Merck Pharmaceutical | Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents |
| US4801600A (en) * | 1987-10-09 | 1989-01-31 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
| US4985429A (en) * | 1987-10-09 | 1991-01-15 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
| US4921869A (en) * | 1987-10-09 | 1990-05-01 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
| US4965268A (en) * | 1987-10-09 | 1990-10-23 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
| US5039690A (en) * | 1987-10-09 | 1991-08-13 | Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents |
| CA1320730C (en) * | 1987-10-16 | 1993-07-27 | The Du Pont Merck Pharmaceutical Company | Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents |
| US4942183A (en) * | 1987-10-16 | 1990-07-17 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents |
| US4977173A (en) * | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
| CA1317594C (en) * | 1987-10-21 | 1993-05-11 | Chung-Ho Park | Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
| US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| US5182403A (en) * | 1988-09-15 | 1993-01-26 | The Upjohn Company | Substituted 3(5'indazolyl) oxazolidin-2-ones |
| US5225565A (en) * | 1988-09-15 | 1993-07-06 | The Upjohn Company | Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones |
| US5231188A (en) * | 1989-11-17 | 1993-07-27 | The Upjohn Company | Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents |
| CA2119556C (en) * | 1991-11-01 | 2004-07-06 | Michael Robert Barbachyn | Substituted aryl- and heteroaryl-phenyloxazolidinones |
| US5380778A (en) * | 1992-09-30 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Fluorochemical aminoalcohols |
| NZ257031A (en) * | 1992-12-08 | 1996-07-26 | Upjohn Co | Tropone substituted phenyloxazolidinone derivatives and anti-bacterial medicaments thereof |
| TW286317B (cs) * | 1993-12-13 | 1996-09-21 | Hoffmann La Roche | |
| US5668286A (en) * | 1994-03-15 | 1997-09-16 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions containing them |
| PT856002E (pt) | 1995-09-01 | 2002-04-29 | Upjohn Co | Feniloxazolidinonas com uma ligacao c-c a aneis heterociclicos de 4 a 8 membros |
| US5883093A (en) * | 1995-09-12 | 1999-03-16 | Pharmacia & Upjohn Company | Phenyloxazolidinone antimicrobials |
| FR2741071B1 (fr) * | 1995-11-09 | 1997-12-12 | Synthelabo | Derives de 3-(benzofuran-5-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique |
| GB9601666D0 (en) * | 1996-01-27 | 1996-03-27 | Zeneca Ltd | Chemical compounds |
| GB9702213D0 (en) | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
| CZ200788A3 (cs) * | 1996-04-11 | 2017-01-25 | Pfizer Inc. | Způsob přípravy 5-aminomethyl substituovaných oxazolidinonaminů |
| GB9609919D0 (en) | 1996-05-11 | 1996-07-17 | Zeneca Ltd | Chemical compounds |
| GB9717807D0 (en) | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Chemical compounds |
| GB9717804D0 (en) | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Chemical compounds |
| EP1028940B1 (en) | 1997-11-07 | 2007-04-18 | Pharmacia & Upjohn Company LLC | Process to produce oxazolidinones |
| GB9725244D0 (en) | 1997-11-29 | 1998-01-28 | Zeneca Ltd | Chemical compounds |
| MXPA00011536A (es) | 1998-06-05 | 2002-10-17 | Astrazeneca Ab | Derivados de oxazolidinona, proceso para su preparacion y composiciones farmaceuticas que las contienen. |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| US6444813B2 (en) * | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| US6410728B1 (en) * | 2000-08-31 | 2002-06-25 | Abbott Laboratories | Oxazolidinone chemotherapeutic agents |
| WO2002018354A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Oxazolidinones and their use as antibacterial agents |
| JP4170753B2 (ja) * | 2000-10-17 | 2008-10-22 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | オキサゾリジノン化合物の製造方法 |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| MX2007001169A (es) * | 2004-08-02 | 2007-03-12 | Hoffmann La Roche | Derivados de benciloxi como inhibidores de la oxidasa de monoamina b. |
| CN102177156B (zh) * | 2008-10-10 | 2016-08-24 | 默沙东公司 | 制备噁唑烷酮类的方法及含有噁唑烷酮类的组合物 |
| CU24089B1 (es) * | 2009-02-03 | 2015-04-29 | Trius Therapeutics | Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona |
| US8580767B2 (en) * | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1180089A (en) * | 1967-10-20 | 1970-02-04 | Delalande Sa | Acetylenic Derivatives of 2-Oxazolidinones and processes of preparation |
| GB1222708A (en) * | 1968-10-22 | 1971-02-17 | Delalande Sa | Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation |
| LU80081A1 (fr) * | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
| FR2435473A2 (fr) * | 1978-08-17 | 1980-04-04 | Delalande Sa | Nouvelles n-aryle oxazolidinones, oxazolidinethiones et pyrrolidinones, leur procede de preparation et leur application en therapeutique |
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| FR2458547B2 (fr) * | 1978-06-09 | 1986-05-16 | Delalande Sa | Nouvelles n-aryle azolones, leur procede de preparation et leur application en therapeutique |
| FR2428032A1 (fr) * | 1978-06-09 | 1980-01-04 | Delalande Sa | Nouvelles oxazolidimones, oxazolidinethiones et pyrrolidinones, leur procede de preparation et leur application en therapeutique |
| CA1171865A (en) * | 1980-06-04 | 1984-07-31 | Alain Lacour | N-aryl azolone derivatives, the process for preparing the same and their application in therapeutics |
-
1981
- 1981-02-25 FR FR8103797A patent/FR2500450A1/fr active Granted
-
1982
- 1982-02-18 IT IT19730/82A patent/IT1153437B/it active
- 1982-02-22 GB GB8205181A patent/GB2094299B/en not_active Expired
- 1982-02-23 LU LU83963A patent/LU83963A1/fr unknown
- 1982-02-24 NL NL8200732A patent/NL8200732A/nl not_active Application Discontinuation
- 1982-02-24 SE SE8201145A patent/SE457258B/sv not_active IP Right Cessation
- 1982-02-24 CH CH1139/82A patent/CH653999A5/fr not_active IP Right Cessation
- 1982-02-24 ES ES509848A patent/ES509848A0/es active Granted
- 1982-02-24 CA CA000396983A patent/CA1178594A/en not_active Expired
- 1982-02-24 AU AU80756/82A patent/AU553462B2/en not_active Ceased
- 1982-02-24 US US06/351,888 patent/US4476136A/en not_active Expired - Fee Related
- 1982-02-25 BE BE0/207402A patent/BE892270A/fr unknown
- 1982-02-25 JP JP57028234A patent/JPS5838273A/ja active Granted
- 1982-02-25 DE DE19823206770 patent/DE3206770A1/de not_active Withdrawn
-
1983
- 1983-02-16 ES ES520180A patent/ES8400729A1/es not_active Expired
-
1984
- 1984-07-13 GB GB08417905A patent/GB2141716B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5838273A (ja) | 1983-03-05 |
| GB2094299A (en) | 1982-09-15 |
| CH653999A5 (fr) | 1986-01-31 |
| AU553462B2 (en) | 1986-07-17 |
| US4476136A (en) | 1984-10-09 |
| BE892270A (fr) | 1982-08-25 |
| GB8417905D0 (en) | 1984-08-15 |
| JPH0261465B2 (cs) | 1990-12-20 |
| FR2500450A1 (fr) | 1982-08-27 |
| GB2094299B (en) | 1985-08-21 |
| IT8219730A0 (it) | 1982-02-18 |
| ES8306707A1 (es) | 1983-06-16 |
| IT1153437B (it) | 1987-01-14 |
| CA1178594A (en) | 1984-11-27 |
| ES520180A0 (es) | 1983-12-01 |
| GB2141716A (en) | 1985-01-03 |
| SE457258B (sv) | 1988-12-12 |
| SE8201145L (sv) | 1982-08-26 |
| FR2500450B1 (cs) | 1983-12-02 |
| DE3206770A1 (de) | 1982-11-11 |
| LU83963A1 (fr) | 1983-09-02 |
| ES8400729A1 (es) | 1983-12-01 |
| ES509848A0 (es) | 1983-06-16 |
| AU8075682A (en) | 1982-09-02 |
| GB2141716B (en) | 1985-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8200732A (nl) | Nieuwe 5-aminomethyl oxazolidineverbindingen, werkwijze ter bereiding daarvan en hun therapeutische toepassing. | |
| EP0373998B1 (fr) | Ethers d'oxime de propénone, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| EP1254139B1 (fr) | Derives de 4-heteroaryl-1,4-diazabicyclo 3.2.2]nonane, leur preparation et leur application en therapeutique | |
| EP0343050B1 (fr) | Dérivés de phényl-6 pipérazinyl-alkyl-3 1H,3H-pyrimidinedione-2,4, leur préparation et leur application en thérapeutique | |
| FR2548666A1 (fr) | Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique | |
| EP0232659B1 (fr) | Nouvelles phényl naphtyridines comportant un substituant méthyle en position 3, et les médicaments qui en contiennent | |
| EP0049203A1 (fr) | Nouvelles benzoxazolinones substituées en 6 par une chaîne aminoalcool ou aminocétone, leur préparation et leur application en thérapeutique | |
| Pierson et al. | Design and synthesis of propranolol analogs as serotonergic agents | |
| EP0213984B1 (fr) | Nouveaux dérivés de l'indole carboxamide, leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments et compositions les renfermant | |
| JPH08510222A (ja) | 欝病、不安神経症およびパーキンソン病を治療するための１−アリールシクロアルキルスルフィド、スルホキシドおよびスルホン | |
| EP0022705B1 (fr) | Nouveaux dérivés du tétrahydropyridinyl-indole et leurs sels, leur préparation, leur application comme médicaments et les compositions les renfermant | |
| LU85423A1 (fr) | Nouveaux derives de la 1,4-dihydropyridine,leur preparation et leur utilisation comme medicaments | |
| FR2662442A1 (fr) | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. | |
| EP0395528B1 (fr) | Dérivés du 4-phénylméthyl 1H-indole, procédé et intermédiaires de préparation, application à titre de médicaments et compositions les renfermant. | |
| EP0172058A1 (fr) | Nouvelles phényl-naphthyridines, leur procédé de préparation, médicaments les contenant, notamment anti-ulcères | |
| EP0201400B1 (fr) | Dérivés du 4-phénylpropyl indole et leurs sels, leur procédé de préparation, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant | |
| EP0338937B1 (fr) | Dérivés du [(hydroxy-4 phényl)-3 hydroxy-1 propyl-1]-1 benzène substitué en position 2 par une chaîne amino-alkylèneoxy, leur procédé de préparation et leur application en thérapeutique | |
| EP0150139A2 (fr) | Dérivés de l'indole éthénylphénol, leurs sels, procédé de préparation, application à titre de médicaments,et compositions les renfermant | |
| JPS63165375A (ja) | オキサゾリジノン−２の５−ヒドロキシエチル誘導体、それらの調製ならびに治療的使用 | |
| FR2547822A1 (fr) | Acylpiperazinoquinazolines substituees utiles comme medicaments et procede pour leur preparation | |
| EP0002156B1 (fr) | Nouveaux dérivés de la 5H-benzocyclohepten-7 amine et leurs sels, leur procédé de préparation, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant | |
| EP0275762B1 (fr) | Dérivés de l'indole carboxamide ainsi que leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments de ces dérivés et compositions les renfermant | |
| EP1023287B1 (fr) | Derives de la 3-oxo-2(h)-1,2,4-triazine en tant que ligands des recepteurs 5ht1a | |
| FR2571965A1 (fr) | Medicaments a base de nouveaux derives de la 4 h-dioxino-(4,5-c)-pyridine. | |
| EP0347305B1 (fr) | [(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |